Please ensure Javascript is enabled for purposes of website accessibility

The Long Wait for This Obesity Drug Is Almost Over

By Brian Orelli, PhD – May 7, 2013 at 1:42PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The DEA issues its final ruling on Belviq, the last step before launch.

It's been a long road, but Eisai and Arena Pharmaceuticals' (ARNA) obesity drug Belviq can finally launch in 30 days. The Drug Enforcement Agency has made its final ruling, assigning a Schedule IV controlled substance designation to the drug.

That's the same recommendation that the Food and Drug Administration made when it approved the drug last June.

It's the same designation Arena said after the approval that it thought it would get in the beginning of this year, based on the typical amount of time it takes for the DEA to issue its rulings.

It's the same designation that the DEA proposed back in December, requesting comments through mid-January.

Nearly a year after the FDA originally approved the drug, the DEA has at last made its final ruling, supporting all of previous recommendations. But the ruling doesn't go into effect for another 30 days, so patients will have to wait until then to get the drug.

A Schedule IV is pretty mild in the classifications for potential abuse. It requires drugmakers to do a little extra paperwork to track where the drugs go, but generally won't affect how the drug is sold.

Belviq's direct competitor, Qsymia from VIVUS (VVUS), has the same Schedule IV designation. Qsymia was actually approved after Belviq, but VIVUS was able to launch earlier because Qsymia inherited its Schedule IV designation from Johnson & Johnson's (JNJ 1.48%) migraine and seizure medication Topamax, which contains the same active ingredient. Before it went generic, annual sales of Topamax peaked at $2.7 billion, highlighting the blockbuster potential for drugs with Schedule IV designations.

Investors have had a long wait -- longer if you include the first rejection -- to see if Belviq can become a blockbuster. They can finally start their 30-day party.

So can the shorts for that matter. For their investment thesis to come to fruition, Belviq has to have lackluster sales. It's a little hard to prove that a drug can't sell well when it isn't even on the market.

As I've said in the past, I don't think the long wait is necessarily the worst thing for the long-term sales of Belviq. VIVUS has done a lot of the ground work, preaching to doctors about the health benefits of losing weight, which will only help Eisai's sales force when it hits the ground. The waiting period also gave Eisai time to work out reimbursement with some insurers, which should make the launch go smoother.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Arena Pharmaceuticals, Inc. Stock Quote
Arena Pharmaceuticals, Inc.
ARNA
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$165.62 (1.48%) $2.42
VIVUS, Inc. Stock Quote
VIVUS, Inc.
VVUS

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
331%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.